Get the Stockscreener App
24.40
2.05%
-0.51
Elanco Animal Health Inc stock is traded at $24.40, with a volume of 5.35M.
It is down -2.05% in the last 24 hours and up +9.81% over the past month.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
See More
Previous Close:
$24.91
Open:
$24.78
24h Volume:
5.35M
Relative Volume:
0.99
Market Cap:
$12.12B
Revenue:
$4.45B
Net Income/Loss:
$205.00M
P/E Ratio:
61.00
EPS:
0.4
Net Cash Flow:
$372.00M
1W Performance:
-0.53%
1M Performance:
+9.81%
6M Performance:
+62.45%
1Y Performance:
+102.32%
1-Day Range:
$24.40
$24.88
1-Week Range:
$23.67
$25.29
52-Week Range:
$8.02
$25.29
Elanco Animal Health Inc Stock (ELAN) Company Profile
Name
Elanco Animal Health Inc
Sector
Phone
877-352-6261
Address
450 ELANCO CIRCLE, INDIANAPOLIS
Compare ELAN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
24.40 | 12.38B | 4.45B | 205.00M | 372.00M | 0.40 |
|
ZTS
Zoetis Inc
|
124.05 | 54.82B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.29 | 50.36B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.46 | 46.00B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.81 | 36.32B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
468.94 | 20.33B | 3.08B | 1.24B | 1.07B | 25.61 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Nov-21-25 | Initiated | KeyBanc Capital Markets | Overweight |
| Nov-19-25 | Upgrade | Argus | Hold → Buy |
| Oct-07-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-17-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jun-26-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-09-24 | Initiated | UBS | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Market Perform |
| Sep-19-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-24 | Upgrade | Stifel | Hold → Buy |
| Dec-19-23 | Initiated | Jefferies | Buy |
| Dec-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Apr-20-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-18-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-16-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Sell |
| Jul-12-22 | Initiated | Piper Sandler | Neutral |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Oct-28-21 | Downgrade | Stifel | Buy → Hold |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jun-15-21 | Upgrade | Cleveland Research | Underperform → Neutral |
| May-11-21 | Upgrade | Barclays | Underweight → Equal Weight |
| May-11-21 | Upgrade | Gabelli & Co | Hold → Buy |
| Apr-15-21 | Initiated | Stifel | Buy |
| Mar-22-21 | Downgrade | Gabelli & Co | Buy → Hold |
| Feb-26-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-09-20 | Downgrade | Argus | Buy → Hold |
| Nov-09-20 | Downgrade | Barclays | Overweight → Underweight |
| Aug-20-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-13-20 | Resumed | Credit Suisse | Neutral |
| Aug-04-20 | Resumed | Goldman | Buy |
| Jul-27-20 | Downgrade | Cleveland Research | Neutral → Underperform |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-20 | Initiated | Raymond James | Mkt Perform |
| Dec-19-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Nov-07-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-19 | Initiated | Barclays | Overweight |
| Aug-26-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-15-19 | Upgrade | UBS | Sell → Neutral |
| May-23-19 | Initiated | Guggenheim | Neutral |
| Mar-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-13-19 | Resumed | Morgan Stanley | Equal-Weight |
| Feb-12-19 | Initiated | William Blair | Mkt Perform |
| Jan-23-19 | Initiated | UBS | Sell |
| Jan-15-19 | Initiated | Argus | Buy |
| Oct-15-18 | Initiated | Morgan Stanley | Equal-Weight |
View All
Elanco Animal Health Inc Stock (ELAN) Latest News
Investment Report: Is Elanco Animal Health Incorporated attractive for institutional investorsWeekly Gains Report & Daily Momentum Trading Reports - baoquankhu1.vn
Piper Sandler Upgrades Elanco Animal Health (ELAN) to Overweight with $30 Price Target - Intellectia AI
Elanco (ELAN) Upgraded by Piper Sandler Amid Corporate Gains - GuruFocus
Elanco Animal Health stock hits 52-week high at 25.0 USD - Investing.com Canada
Elanco upgraded, Zoetis downgraded at Piper Sandler (ELAN:NYSE) - Seeking Alpha
Piper Sandler upgrades Elanco as co gains traction with veterinary groups - Investing.com Canada
Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement - Finviz
Breaking Down Elanco Animal Health: 5 Analysts Share Their Views - Benzinga
Alphabet To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Elanco (ELAN) Upgraded by Analyst with Increased Price Target - GuruFocus
Piper Sandler Upgrades Elanco Animal Health (ELAN) and Raises Pr - GuruFocus
This Elanco Animal Health Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
Feline Vaccines Market Overview and Leading Players: Merck & Co, - openPR.com
Elanco Animal Health Incorporated $ELAN Shares Acquired by Amalgamated Bank - MarketBeat
Pet Pharmaceuticals Market Is Booming Worldwide 2026-2033 | Zoetis • Merck Animal Health • Elanco Animal Health - openPR.com
Animal Parasiticides Market with Insights from Boehringer - openPR.com
Animal Health Market Overview and Leading Players: Bayer, Ceva - openPR.com
Elanco Animal Health (NYSE:ELAN) Hits New 1-Year High on Analyst Upgrade - MarketBeat
Elanco Animal Health Incorporated (NYSE:ELAN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Elanco Animal Health (ELAN) Stock Analysis: Navigating Growth Potential Amidst Market Dynamics - DirectorsTalk Interviews
Poultry Antibiotic Market Is Booming Worldwide 2026-2033 - openPR.com
The Glucosamine Supplements for Dogs Market, Global Forecast 2026-2032 | Innovation Drives Canine Glucosamine Supplement Market with New Chewable and Liquid Formats - GlobeNewswire Inc.
Veterinary Vaccines Market to Reach USD 236 Million by 2031 | CAGR - openPR.com
Anticoccidial Drugs Market to Reach USD 2.52 Billion by 2033 | - openPR.com
Elanco Animal Health (NYSE:ELAN) Upgraded by Wall Street Zen to Strong-Buy Rating - MarketBeat
State of Alaska Department of Revenue Takes Position in Elanco Animal Health Incorporated $ELAN - MarketBeat
New York State Teachers Retirement System Invests $5.50 Million in Elanco Animal Health Incorporated $ELAN - MarketBeat
ASR Vermogensbeheer N.V. Trims Holdings in Elanco Animal Health Incorporated $ELAN - MarketBeat
Institution Moves: What is the next catalyst for Elanco Animal Health IncorporatedJuly 2025 Sentiment & Capital Efficient Trading Techniques - baoquankhu1.vn
Nisa Investment Advisors LLC Lowers Stock Holdings in Elanco Animal Health Incorporated $ELAN - MarketBeat
Investor Mood: Can Elanco Animal Health Incorporated reach all time highs this yearTrade Exit Report & AI Optimized Trade Strategies - baoquankhu1.vn
Risk Hedge: Can Elanco Animal Health Incorporated ride the EV wave2025 Biggest Moves & Reliable Entry Point Alerts - baoquankhu1.vn
Elanco Animal Health stock hits 52-week high at 24.51 USD - Investing.com Canada
Oregon Public Employees Retirement Fund Invests $2.01 Million in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health Incorporated $ELAN Shares Purchased by SG Americas Securities LLC - MarketBeat
Veterinary Oncology Market Is Going to BoomGrowth - openPR.com
Merger Talk: Why Elanco Animal Health Incorporated stock could outperform in 2025July 2025 Action & High Accuracy Buy Signal Tips - moha.gov.vn
Elanco CEO: Gaining Market Share Via 'Major' Innovations - marketscreener.com
Elanco Animal Health (NYSE:ELAN) Sets New 52-Week HighHere's Why - MarketBeat
Trend Recap: What is the PEG ratio of Elanco Animal Health IncorporatedBull Run & Long-Term Safe Investment Ideas - baoquankhu1.vn
Elanco Animal Health Inc Presents at J.P. Morgan Healthcare Conference - TradingView
Elanco Animal Health (NYSE:ELAN) Downgraded by Wall Street Zen to "Buy" - MarketBeat
Louisiana State Employees Retirement System Makes New Investment in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health: Innovation-Led Growth Model Plus Credible Deleveraging Path (ELAN) - Seeking Alpha
Will Elanco Animal Health Incorporated stock benefit from automation2025 Performance Recap & Reliable Breakout Forecasts - ulpravda.ru
Will Elanco Animal Health Incorporated (5EA) stock outperform value peers2025 Major Catalysts & Smart Investment Allocation Tips - ulpravda.ru
S P Trends: Will Elanco Animal Health Incorporated stock outperform energy sector in 2025Market Performance Report & Technical Analysis for Trade Confirmation - ulpravda.ru
Will Elanco Animal Health Incorporated stock outperform energy sector in 2025Market Movement Recap & Daily Profit Maximizing Tips - ulpravda.ru
Assessing Elanco Animal Health (ELAN) Valuation After Befrena Approval And Turnaround Progress - Yahoo Finance
Veterinary Pain Management Drugs Market to hit US$ 3.00 Billion - openPR.com
Elanco Animal Health (NYSE:ELAN) Hits New 1-Year HighHere's What Happened - MarketBeat
Elanco Animal Health Inc Stock (ELAN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
2.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):